Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Mullerian hormone receptor, type II (AMHR2), a promising target for ovarian cancer prevention and treatment. Anixa’s ovarian cancer vaccine, being developed in a collaboration between Cleveland Clinic and the National Cancer Institute, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Positive Outlook for Anixa Biosciences: Promising Cancer Treatment Trials Justify Buy Rating
- Anixa initiates dosing in fourth cohort of ovarian cancer CAR-T trial
- Anixa Biosciences announces poster presentation on Ovarian cancer CAR-T trial
- Promising Developments at Anixa Biosciences: Buy Rating Reiterated with $7 Price Target
- Anixa Biosciences completes enrollment in Phase 1 trial of breast cancer vaccine